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Patients  who develop thrombocytopenic purpura  as a  result  of sensitivity 
to some drugs have in their serum an antibody which  fixes complement only 
when the antibody is present together with platelets and the offending  drug. 
This was first demonstrated by Ackroyd in the case of purpura due to sedormid 
sensitivity  (1-5).  In  addition  he  determined  a  number  of  the  qualitative 
properties  of  the  antibody-drug-platelet  complex.  Subsequent  reports  con- 
cerning  purpura due to other drugs, reviewed by Ackroyd (6), suggested that 
the immunological  mechanism  involved was  similar.  From  the  observations 
of Bolton (7)  it was evident that  the reactions of the antibody formed as a 
result  of  quinidine  sensitivity  had  all  of  the  qualitative  properties  of  the 
reactions of the antibody resulting from sedormid sensitivity which Ackroyd 
reported. It therefore appeared that study of the reactions involving the anti- 
body of quinidine  purpura  might  provide  information  concerning  a  general 
type of immunologic  response which has possible relevance to various diseases 
of sensitivity. 
An interpretation  of the mechanism  of the molecular associations and  the 
sequence of the reactions involved in formation of the antibody-drug-platelet 
complex was based on analysis of the effects of varying the initial concentra- 
tion  of each component in the complex on the amount of complement fixed 
by the complex,  and on kinetic aspects of complex formation. A steric model 
for formation  of the  complex and  fixation  of complement  by the  complex, 
which was deduced from experimental results, was described mathematically 
by Dr. Terrell L. Hill. Theoretical results calculated using equations based on 
the model were consistent in all respects with experimental results. 
Materials and Methods 
Source of Antibody.--Antibody which was used was in the serum of a patient who developed 
purpura as a  result of sensitivity to quinidine (see Paper IV of this series, patient E.K.S.). 
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The antibody was stable on storage at  -20  ° indefinitely. Serum containing antibody was 
heated as routine at 56  ° for 30 minutes immediately before use in complement fixing reactions. 
Saline.--O.147 molar sodium chloride. 
Q.uinidine and Oth** Cinchona Alkaloids.--Highly purified cinchona alkaloids dissolved in 
saline were used. Quinidine gluconate, MW 524,  62.3  per cent anhydrous quinidine, was 
obtained from Eli Lilly and Company. Quinine dihydrochloride (neutralized with I 1~ sodium 
hydroxide), MW 397, 81.7 per cent anhydrous quinine; cinchonine sulfate,  (Ct~H~ON2)2. 
H2SO,.2H20, MW 723, 81.4 per cent anhydrous cinchonine; and cinchonidine sulfate, MW 
74i,  79.4 per cent anhydrous cinchonidine, were  obtained from Merck  & Company, Inc. 
Quinidine was measured spectrophotometrically by the method of Josephson a  a/. (8). 
Preparation of Platdet Suspension.--All surfaces  in contact  with  platelets  during the 
preparation of suspensions were  siliconed.  Venous blood was run directly into test  tubes 
containing anticoagulant (one part 1.S per cent by weight of the disodium salt of ethylenedi- 
aminetetraacetic acid, pH 7, to nine parts of blood). Platelet-rich plasma was obtained by 
centrifuging blood at 200 g for 15 minutes and drawing off the supernatant plasma. Packed 
platelets were obtained by centrifuging platelet-rich plasma at 2500 g for 30 minutes. Platelet 
suspensions were made by washing the platelets once with 1 per cent ammonium oxalate, 
followed by two washes in saline and resuspension in saline. Platelet counts were performed 
by the method of Brecher and Cronkite (9),  using three pipettes and three chambers. The 
mean volume of packed platelets in fresh suspensions, determined using a  microhematocrit 
technique (I0), was 1.67 volumes per cent when the platelet concentration was 10s/ram.  8, 
with a standard deviation of 0.032 volumes per cent. In this work the number of platelets/ 
ram3 has the same meaning as a concentration of platelets. 
Measurement o/ Complement Aai~y.--Complement  activity was determined by methods 
outlined by Kabat and Mayer  (11),  employing sheep  erythrocytes and rabbit antiserum 
(hemolysin). The concentration of erythrocytes in the presence of  1:2000  hemolysin was 
adjusted so that 0.5 ml. of sensitized cells produced a density of 0.760 at 540 m/~ (Beckman 
DU spectrophotometer) when completely hemolyzed ina total volume  of 3.75 ml. Amounts of 
complement are expressed  in units, one unit being defined as that amount of complement 
required to hemolyze 50 per cent of the cells in 30 minutes at 37 °. With the hemolysin which 
was used throughout this work, 2.1 -v 0.I X  10  --8 ml. of pooled fresh guinea pig serum was 
required for 50 per cent hemolysis. 
Complement was titrated by determining the amount of solution which produced 50 per 
cent hemolysis,  interpolating on a curve with at least three points in the 20 to 80 per cent 
hemolysis range. The amount of complement added  to a  complement-fixing mixture was 
adjusted whenever possible so that the amount of complement fixed was in the range of 25 
to 75 per cent of the total amount of complement added. Complement fixation was carried out 
as routine in a 0.5 ml. volume for 1 hour at room temperature with frequent agitation of the 
tubes. Suspended material (platelets) was removed from the fixation mixture by centrifuga- 
tion before residual complement was titrated. 
EX~ER~NTS  AND  P,  ESULTS 
1.  Effects  of  Varying  Plalelet  and  Antibody  Concenlration.--In  Table  I  it 
can  be  seen  that  the  amount of  complement fixed  by  a  mixture  containing 
antibody, platelets, and quinidine was independent of complement concentra- 
tion and that up to  82 per cent of the added complement could be consumed 
during  fixation  without  affecting  the  total  amount  fixed.  The  amount  of 
complement fixed was  directly proportional  to  the  concentration of platelets 
over the range of platelet concentrations used in Table I  when antibody con- N.  RAPHAEL  SHULMAN  667 
centration was kept constant. The curves of Fig.  1 show  the effects of wide 
variations in platelet concentration on complement fixation using three  dif- 
ferent concentrations of antibody. The points of the initial linear portion of the 
uppermost curve in Fig.  1  were  taken from Table I.  Increasing the platelet 
TABLE I 
Variation in Platda Concentration, Different Amounts of Complanent 
Volume in each tube brought to 0.5 ml. with saline. Column 1, patient's serum containing 
antibody. Column 2, suspension contained  2.5  X  10  e platelets/mm, s.  Column 3, solution 
contained 8 rag. quinidine gluconate/ml.,  final concentration in mixture 10  -'2*t M qninidine. 
Column 4, fresh pooled guinea pig serum (G.p.s.). After incubating the complement-fixing 
mixture (columns 1 +  2 +  3 +  4) for one hour at room temperature, platelets were removed 
by centrifugation.  Column 5, the amount of supernatant fluid required to produce 50 per 
cent hemolysis was determined  using appropriate  dilutions of supernatant fluid to permit 
pipetting aliquots greater  than 0.1 ml. into hemolysis mixture.  Controls, representing full 
complement activity of 0.16 mL of G.p.s., required an average of 0.625 X  10  -3 mi. of super- 
natant fluid to produce 50 per cent hemolysis (i. e. average of values in column 5 for tubes 
10,  11,  12, and 13). The complement activity of 0.16 ml. of G.p.s. was equal to 80 units 
(0.5 +  0.625 X  10-3). Column 6, per cent complement fixed calculated from milliliters of 
supernatant fluid required for 50 per cent hemolysis in experimental tubes compared to con- 
trol tubes. Column 7, per cent complement fixed times units of corn ~lement used. 
1 
Tube  Antibody 
ml. 
1  0.18 
2  0.18 
3  0.18 
4  0 
5  0.18 
6  0.18 
7  0.18 
8  0.18 
9  0.18 
10  0.18 
11  0.18 
12  0 
13  0 
P la t2elet  Q  u in3idine 
suspensxon  solution 
0.04  0.04 
0  0 
0.01  0.04 
0.02  0.04 
0.04  0.04 
0.06  0.04 
0.08  0.04 
0  0.04 
0.08  0 
0.08  0.04 
0  0 
4 
G.p.s. 
ml. 
0.08 
0.08 
0.08 
0.08 
0.16 
0.16 
0.16 
0.16 
0.16 
0.16 
0.16 
0.16 
0.16 
5 
Supernatant 
fluid for 
50 per cent 
hemolysis 
ml.  X  lO-t 
1.538 
2.190 
6.865 
1. 254 
0.695 
0. 752 
1.030 
1.525 
3.470 
0. 623 
0. 629 
0.625 
0.621 
6 
Complement 
fixed 
#er Cb~tt 
18.7 
43.0 
81.8 
10.0 
19.2 
39.3 
59.1 
82.0 
7 
Complement 
fixed 
units 
7.5 
17.2 
32.7 
8.0 
15.4 
31.4 
47.2 
65.6 
concentration in the presence of a  constant concentration of antibody led to a 
maximum amount of  complement fixation, but further  increases in platelet 
concentration  then  resulted  in  a  gradual  decrease  in  complement fixation 
until an asymptotic value much lower than the maximum was reached.  The 
maximum amount  of  complement fixed  and  the  concentration of  platelets 
necessary for maximum complement fixation were proportional to the amount 
of antibody used. 668  IMMUNOREACTIONS  INVOLVING  PLATELETS,  I 
When antibody concentration was increased in the presence of a  constant 
concentration of platelets, complement fixation reached an asymptotic maxi- 
mum directly proportional to the concentration of platelets as shown in Fig. 2. 
Depression of the initial portion of the curves is due to the high platelet: anti- 
body ratio in this region (cf. Fig. 1). 
Because complement fixation was directly proportional to platelet concen- 
tration when antibody concentration was relatively high, under these condi- 
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FIO.  1. Effects of wide variations in platelet concentration using three different amounts 
of antibody. Conditions as in Table I  with concentrations of added reagents appropriately 
altered to maintain the volume of complement-fixing mixture at 0.3 ml. 
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tions, platelets could be considered to be fully saturated with antibody and the 
amount  of  complement  fixed  related  to  the  absolute  amount  of  antibody 
adsorbed. The decrease in complement fixation which occurred when platelet 
concentration  was  increased  above  an  optimum  value  suggested  that  the 
amount of complement fixed was related not only to the absolute amount of 
antibody adsorbed but also to the amount adsorbed per platelet. 
2.  Definition  of an Antibody  Unit.- 
In Fig. 1 it was seen that the maximum amount of complement fixed and the concentration 
of platelets necessary for maximum complement fixation was dependent on the concentration 
of antibody used. The concentration of platelets required for maximum complement fixation 
was found to be directly proportional to antibody concentration with amounts of antibody •  N. RAPHAEL  SR'ULM.AN  669 
which fixed as much as 120 units of complement. As shown in Fig. 3 the maximum amount of 
complement fixed in the presence of an optimal concentration of platelets was directly pro- 
portional to antibody concentration as long as the  amount of antibody used in 0.5  ml.  of 
reaction mixture fixed  no more than approximately 45  units of complement. Amounts of 
antibody therefore could be expressed in terms of units based on the concentration of platelets 
required for maximum complement fixation for any amount of antibody or on the maximum 
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FiG. 2. Effects of varying antibody concentration with platelet concentration constant. 
Conditions as in Fig. 1. 
amount  of complement fixed for amounts of antibody which fixed up to 45 units of comple- 
ment. One unit of antibody was defined as that amount of antibody in a 0.5 ml. volume which 
gave maximum complement fixation with  10  s  platelets/mm.  8 or which fixed  10.5 units of 
complement when the platelet concentration was optimal. A  0.1  ml.  aliquot of  the serum 
sample used in Fig. 3 contained sufficient antibody to fix 42 units of complement when the 
platelet concentration was optimal at 4  X  105/ram. 8. Thus 0.1 ml. of this serum contained 4 
units of antibody. When measurements were made using an aliquot of 1 serum sample on 
10 separate occasions over a period of several months with platelet suspensions obtained from 
a  different donor each  time,  the concentration of platelets giving maximum complement 
fixation per unit of antibody varied 21 per cent from the mean of 105/ram. 3 and the number 
of units of complement fixed varied 9 per cent from the mean of 10.5 units. 670  IMMUNOI~EACTIONS INVOLVING PLATELETS. I 
3. Effects of Varying Quinidine Concentration.--The amount of complement 
fixed by a  constant concentration  of antibody and platelets  as a  function of 
quinidine  concentration  is  shown  in  Fig.  4.  Complement  fixation  was  not 
detectable with up to 10.2 units of antibody and an optimal anfibody:platelet 
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FIG. 3. Effects of increasing the concentration of antibody and platelets while maintaining 
an optimal antibody:platelet ratio.  Conditions as in Fig. 1; same serum sample. A platelet 
concentration  of 4 X  10s/ram? produced maximum complement fixation with 0.1 ml. of pa- 
tient's serum when determined as in Fig. 1. In other tubes the same ratio of platelet concen- 
tration to antibody concentration was maintained. The dashed line is a projection of the linear 
portion of the experimental curve to show more clearly the deviation with higher antibody 
and platelet concentration. 
ratio when the quinidine concentration was 10  -6." M, and was measurable only 
with high concentrations of antibody when quinidine concentration was 10  °6 ~. 
The amount of complement fixed increased with logarithmic increases in quin- 
idine  concentration  and  reached a  maximum  with all  concentrations of anti- 
body when the quinidine  concentration was in the range  of 100  8'16 to 10  -~-Ts ~. 
Further  increases  in  quinidine  concentration  then  resulted  in  decreasing 
amounts  of  complement  fixed.  When  quinidine  concentration  was  greater N.  RAPIIAEL SIII/LMAN  671 
than 10  -2 "~ M, loss of complement activity occurred in control mixtures and was 
associated with visible precipitation in the mixtures. Because this may have 
had some non-specific effect on the fixation of complement by the antibody- 
quinidine-platelet complex, the portions of the curves in which quinidine was 
anticomplementary are  represented  by  dashed  lines.  Complete  anticomple- 
mentary activity of 10  -1"6e ~  quinidine prevented use of higher concentrations. 
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Fro. 4. Effects of varying qninidine concentration. Amounts of antibody are expressed in 
units as defined in text. The platelet concentration used with each amount of antibody was 
kept constant at that concentration  which gave maximum complement fixation when quinidine 
concentration was optimal. The amount of complement inactivated by qninidine alone at con- 
centrations greater than 10  --2"z molar was subtracted from the total amount fixed to obtain 
the plotted values. 
A  quinidine concentration  of  10  -2"914 ~r  (0.64  mg.  quirddine  gluconate/ml.) 
was used as an optimal concentration in the above experiments. 
4.  Amount  of Complement  Fixed  and  Amount  of Antibody  Adsorbed  as  a 
Function of Platelet Concentration at Different Quinidine Concentrations.--Fig.  5 
shows complement fixation as a function of platelet concentration at different 
concentrations of quinidine. One amount of antibody was used  (5.14  units). 
Although  the  maximum amount of  complement fixed  was  decreased  when 
quinidine concentration was sub-optimal or above optimal, the concentration 
of  platelets  required  for  maximum  complement fixation remained  approxi- 
mately the same. In Fig. 5 the maximum amount of complement which could 672  IMMUNOP.EACTIONS  INVOLVING  PLATELETS.  I 
be fixed by a  single amount of antibody was limited by quinidine concentra- 
tion, whereas in Fig. 1 the maximum amount of complement which could be 
fixed was limited by antibody concentration. The relationships in Fig.  1 are 
duplicated in Fig. 5 by the uppermost solid line curve (5.14 units of antibody) 
and the dashed line curve  (2.57  units of antibody), both of which were ob- 
tained using an optimal concentration of quinidine. 
If decreases in complement fixation at high and low quinidine concentrations 
were related simply to decreased amounts of antibody attaching to platelets, 
the  relationship between platelet concentration and  complement fixation in 
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FIo. 5. Complement fixation as a function of platelet concentration at different concen- 
trations of quinidine. See text. Conditions  as in Fig. 4. 
Fig. 5 might be expected to be more nearly like that in Fig. 1. It seemed there- 
fore that the amount of antibody adsorbed per platelet was not the only factor 
determining the amount of complement fixed at different quinidine concentra- 
tions. 
The effect of quinidine concentration on adsorption of antibody by platelets 
is shown in Fig. 6. The amount of antibody adsorbed by platelets in mixtures 
of antibody, quinidine, and platelets is compared with the amount of comple- 
ment fixed by the same mixtures. The uppermost dashed line represents  the 
amount of complement fixed and the uppermost solid line represents the amount 
of antibody adsorbed when quinidine concentration was optimal at 10  -2'9t ~. 
Maximum complement fixation was obtained when the platelet concentration 
was approximately 2 X  105/mm3; and, at this concentration of platelets, ap- N.  RAPHAEL  SHULM.AN  673 
proximately 70 per cent of the antibody was adsorbed. More antibody was ad- 
sorbed when platelet  concentration was  increased  but  the net  result was  a 
decrease in the amount of antibody adsorbed per platelet and in the amount of 
complement fixed.  When quinidine concentration was above optimal at 10  -1"8T re, 
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FIG.  6.  Effect of quinidine concentration  on  adsorption  of antibody  by platelets.  Two 
units of antibody used; 100 per cent complement fixation equivalent to 21 units of comple- 
ment fixed. Dashed lines are curves of complement fixation obtained as in Fig. 5 at the con- 
centrations of quinidine indicated on the graph. Similar mixtures of antibody,  platelets, and 
quinidine but without complement were used to measure amounts of antibody adsorbed  at 
selected concentrations of platelets. After incubation for 1 hour, platelets with adsorbed anti- 
body  (complexes)  were removed from the mixtures by centrifugation.  Antibody remaining 
in the supernatant fluid of each mixture was titered as in Fig. 1 using aliquots of the super- 
natant  fluid in the usual complement fixation mixture with various concentrations of fresh 
platelets  and  sufficient  additional  quinidine  to  give  an  optimal  quinidine  concentration. 
Antibody in the supematant fluid of mixtures containing above-optimal quinidine was meas- 
ured after the supematant fluid had been dialyzed for 48 hours at 5 ° against saline to remove 
excessive quinidine. The curve of antibody adsorption represented by (D--~)  was obtained 
with 10  -6'1° g  quinidine; there is no corresponding dashed-line curve of complement fixation 
because no measurable amount of complement was fixed at any concentration of platelets. 
the amount of antibody adsorbed per platelet was so similar to that at optimal 
quinidine concentrations that only a single curve could be drawn through both 
sets of experimental points. The maximum amount of complement fixed at the 
higher  concentration  of  quinidine  was,  however,  greatly  reduced.  When 
quinidine  concentration  was  progressively  decreased  below  optimal,  less 
antibody was adsorbed per platelet and less complement was fixed. However, 
the  amount  of complement  fixed  was  decreased  much  more  than  was  the 
amount  of  antibody adsorbed  per  platelet.  At  very  low  concentrations  of 674  IMMUNOREACTIONS  INVOLVING  PLATELETS.  I 
quinidine,  antibody was  adsorbed  on platelets in  spite  of  the  fact that no 
complement fixation could be measured [e.g., 10  -e'l" ~]. 
Although equivalent mounts  of  antibody were  adsorbed per  platelet  at 
optimal and above optimal quinidine concentration, the amount of complement 
fixed was less with above optimal quinidine concentration. With suboptimal 
concentrations  of  quinidine,  decreases  in  the  amount  of  complement fixed 
were relatively greater  than decreases in the  amount of antibody adsorbed 
per platelet. These findings could be explained if attachment of antibody to 
platelets could occur  with different numbers  of qumidine molecules,  and if 
complement were fixed only when the attachment occurred with an optimal 
number of quinidine molecules but not with too few or too many quinidine 
molecules. 
5.  Rates of Complement Fixation  with Different  Concentrations of Quinidinc 
and  Antibody.--In  Fig.  7 the  rates  of complement fixation are  shown when 
quinidine concentration was sufficient to give maximum complement fixation 
(curve 1),  and when complement fixation was decreased because of too little 
quinidine (curves 3  and 5)  and too much quinidine (curve 6),  all with the 
same concentration of antibody and platelets. The rate of complement fixa- 
tion was proportional to the concentration of quinidine. This was true even 
when the final amount of complement fixed was decreased at above optimal 
concentrations of quinidine (curve 6).  All curves approached an asymptotic 
maximum which did not change significantly after incubation for 1 hour. 
That  the  rate  of complement fixation represented  the  rate  of  antibody- 
quinidine-platelet complex formation can be seen by comparing curves 1 and 
7.  Curve 7 was obtained by permitting the complex to form under the same 
conditions as for curve 1 for 1 hour before complement was added. The pre- 
formed complex immediately fixed most of the complement which was to be 
fixed.  When  complement  was  present  before  formation  of  the  complex  in 
mixtures which gave rapid complement fixation when quinidine concentration 
was high (curve 6),  there was no delay in fixing the total amount of comple- 
ment which was to be fixed. It would appear that complement, when present 
during formation of the complex, is fixed even more rapidly than indicated 
in curve  7;  and that the rate  of complement fixation actually indicates the 
rate of complex formation. It is evident from the above experiment that com- 
plement fixation is a reaction subsequent to antibody-quinidine-platelet com- 
plex formation. 
Curve 2 shows the rate of complement fixation when quinidine concentra- 
tion was the same as in curve 1 but antibody concentration was half that in 
curve 1. Similarly, quinidine concentration in curve 4 was the same in curve 3 
but antibody concentration was decreased by half. The experimental points 
permitted drawing curves 1 and 2 and curves 3 and 4 as twofold multiples with 
the same reaction half-times which are indicated by arrows. The fact that the N.  RAPHAEL  SHULMAN  675 
half-time of the reaction at any one concentration of quinidine was independent 
of the concentration of antibody indicated  that the rate  constant of  the re- 
action was dependent on quinidine concentration alone. It therefore appeared 
that  the  amount of  quinidine present,  even  at  low quinidine concentrations 
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Fro. 7. Rates of complement fixation with different concentrations of quinidine and anti- 
body. The concentration of platelets used with 2.34 and 1.17 units of antibody was the same 
(2.0  X  105/mm.3).  Rate of complement fixation was measured beginning after the addition 
of quinidine which was the last reagent added to the complement-fixing mixtures. Mixtures 
were agitated continuously after addition of complement. In curve 7, complement was added 
1 hour after other reagents and timing was begun after addition of complement. Complement 
fixation was stopped at the different time intervals by diluting the complement-fixing mixture 
20-fold  and  immediately  removing  platelets  by  centrifugation.  With  anticomplementary 
concentrations of quinidine, controls were run at each time interval. 
which resulted in decreased complement fixation (e.g. curves 3 and 4), was in 
large excess compared to the amount of antibody. 
6.  Attempts to Distinguish Steps in the Reaction.--The following experiments 
were done in  an attempt to determine whether a  reaction occurred between 
quinidine and antibody or quinidine and platelets, one of which appeared to 
be essential as the initial step of the over-all reaction. 
(a) Effects  of order of addition  of reagents: 
Antibody and quinidine, platelets and  quinidine, and platelets and antibody, were incu- 
bated together in the presence of complement before the third component of the complex was 676  ~NOREACTIONS  INVOLVING  PLATELETS. I 
added and the rate of complement fixation determined as shown in Fig. 8. Preincubating any 
two components of the complex before adding the third produced no difference in the rate of 
complement fixation.  Similar experiments done at  25  °  with quinidine concentration 10  -~'9 
and l0  -5"36 3~ and with antibody and platelet concentration fourfold that of Fig. 8 also resulted 
in no detectable difference in rate due to pre-incubating any two components. When platelets 
and antibody were pre-incubate.d separately in 10  -4,46 M qninidine and the third component 
was added along with sufficient saline to produce a fivefold dilution of the incubated reagents, 
bringing the final qninidine concentration to 10  -5"16 ]~, the rate of complement fixation was the 
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Fio. 8. Effect of order of addition of reagents on rate of complement fixation at different 
temperatures. An optimal platelet concentration was used with 2.2 units of antibody in the 
presence  of  10  ~'16 M quinidine.  (O--O)  antibody and  quinidine preincubated,  (O--O) 
platelets and quinidine preincubated,  (A--ZX)  antibody and platelets preincubated for 15 
vain. in presence of complement before the missing reagent was added and complement fixa- 
tion determined as in Fig. 7. Both pre-incubation and complement fixation were carried out 
at the temperatures indicated on the graph.  Each point is the average of two determina- 
tions. There was no loss of complement activity at 45  ° in control tubes during the experimental 
period. 
same in each case and was equal to that obtained when quinidine was added as the third 
reagent to give a  final concentration of 10  ~'le M. It therefore appeared that association of 
either quinidine and antibody or quinidine and platelet as well as the reverse reaction occurred 
very rapidly compared to the rate of formation of the complete complex. 
It was considered that an isomer of quinidine might retard equilibrium formation by com- 
peting with quinidine for sites of attachment. It was found that cinchonine on a  molar basis 
was as effective as quinidine in complement-fixing reactions whereas quinine and cinchonidine 
were l0 s times as effective, their small amount of activity being due no doubt to incomplete 
separation of the isomers. In the one case, antibody was incubated with 10  -*'re •  quinine 
(or cinchonidine) followed by addition of platelets mixed with quinidine to give a final quini- 
dine concentration of 10  ~'t6 •;  and in the other case, platelets were incubated with los "is M 
quinine (or cinchonidine) followed by addition  of antibody mixed with  quinidine to give a N.  RAPHAEL  SHULMAN  677 
final quinidine concentration of I0  -6"x° M. The rate of complement  fixation was the same in 
each case and was equal to that obtained with lff  "6"xe ~  quinidine when no  quinine or cin- 
chonidine was present. The isomers, quinine and cinchonidine, did not measurably interfere 
with the rate of complement fixation when present at  a  concentration  100-fold  that of  a 
suboptimal quinidine concentration. 
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FIo.  9. Rate of removal of quinidine from normal serum and serum containing antibody 
by dialysis against saline. Quinidine was added to a  normal serum sample, to pooled serum 
from five normal individuals, and to the patient's serum containing 32 units of antibody/ml. 
to give a final concentration of 10  -l"ss ~  quinidine. Four 1 ml. aliquots of each serum sample 
were all dialyzed together in ~,~ inch dialysis tubing against 3 I. of saline at 8  °. At 8, 18, 42, 
and 49 hours the dialysis fluid was changed. At 18, 42, 47, and 68 hours quinidine concentra- 
tion in an aliquot of each serum sample was measured by using 0.2 ml. of the serum sample 
as  the source  of quinidine in  the usual  complement-fixing mixture with optimal piatelets 
and a  0.5 ml. total volume. When measuring quinidine content of normal serum, 0.2 ml. of 
the patient's plain serum dialyzed against saline in a  separate container was used as a source 
of antibody, and 0.2 ml. of plain normal serum dialyzed against saline was added to the mix- 
ture when measuring quinidine content of the patient's serum. Quinidine concentration was 
determined by the amount of complement fixed using a reference curve prepared as in Fig. 4 
with mixtures of dialyzed patient's and normal serum and known concentrations of quinidine. 
Original quinidine concentration in all samples  (~),  concentration in single normal serum 
sample (@--@), in pooled normal serum (O--O), and in serum containing antibody (/k--A). 
It was noted that after the 8 hour change of dialysis fluid the concentration of quinidine in 
the dialysis fluid was too low to measure; i.e., less than 10  -e'2 M. 
(b)  A finity  of serum  containing  antibody  and  normal serum for quinidine: 
In an attempt to determine whether the presence of antibody increased  the non-specific 
affinity of serum for quinidine, the rates of removal of quinidine from serum containing anti- 
body and from normal serum by dialysis were compared, as shown in Fig. 9.  The presence of 
antibody in amounts up to 32 units/ml, had no measurable effect on the binding of quinidine 678  IMMUNOREACTIONS  INVOLVING  PLATELETS.  I 
TABLE II 
Treatment  of Platelets to Decrease Their Nitrogen  Content and Maintain  Their 
Complement-Fixing  A ctivity 
Column 1, all procedures done at 25  ° unless otherwise indicated. All platelet preparations 
could be stored at 5  ° for at least  1 week without loss  of activity.  Column 2,  observations 
under phase microscopy. Column 3, per cent activity based on relative volume of suspensions 
required to produce equivalent increments of complement fixation in the presence of excess 
antibody  and  optimal quinidine in the usual  complement-fixing mixture; 0.01  ml. of sus- 
pension 1 fixed 3.8 units of complement. Column 4, 100 per cent nitrogen content equivalent 
to 0.94 rag.  nitrogen/ml, of suspension,  determined by semi-micro-Kjeldahl technique. Col- 
umn 5, ratio of complement-fixing activity to nitrogen content. 
1 
Platelet preparation 
No.  1:  Suspension in saline prepared 
as in Materials and Methods plate- 
let conc. 2 ×  106/ram3 
No. 2: Platelets sedimented from Prep. 
1 (2000  g  ×  15 min.) incubated  1 
hr. in each of 3 changes of distilled 
water  5  times  original  suspension 
volume.  Final  suspension  in  orig- 
inal volume of saline, plate.let  conc. 
1.5 ×  10S/mm? 
No.  3:  Prep.  1  quick-frozen  and 
thawed  3  times,  then  washed  $ 
times in distilled water.  Final sus- 
pension  in  original  volume  of 
saline platelet conc. approx.  1.3  × 
106/ram. a 
No. 4: Prep. 3 centrifuged 1000 g for 
10  rain.  ppt.  discarded.  Superna- 
taut  fluid centrifuged  14,000  g  for 
10  min., ppt.  resuspended  in orig- 
inal volume of saline, platelet conc. 
1.8 ×  106/mm? 
2 
Appearance of platelets 
Similar to fresh platelets in 
plasma 
Discrete,  moderately  swol- 
len, slightly less refractile 
with irregular membranes 
containing numerous spic- 
ules.  Some  unaltered 
Many discrete but numerous 
small  clumps.  Almost  all 
greatly  swollen,  non-re- 
fractile  and  granular, 
membranous  margins  in- 
distinct  (i.e.  "ghosts"). 
Few as in No. 2 
As in No. 3 but all discrete 
3 
'.omple- I 
ment  I 
fixing! 
ctivity 
~0  Cent  , 
72 
63.7 
10.4 
4  5 
qitrc-  Column 
gen  3/Col- 
ontet  umn 4 
00  1.0 
58.7  1.23 
32.1  1.99 
1.75  5.95 
by serum.  Because normal  serum proteins  adsorb  quinidine so strongly, their presence in 
such relatively high concentration  may have masked  possible  specific binding of quinidine 
by antibody. 
In the reverse experiment in which one volume of plain normal serum and  plain patient's 
serum (32 units of antibody/ml.) were dialyzed in separate dialysis bags against 1,000 volumes 
of 10  -6 M quinidine, the concentration of quinidine in both serum samples  reached 10  ~'6 u 
in 24 hours at 5  °, as determined using techniques of Fig. 9. Thus it would appear that antibody 
had at least the same ability as normal serum oroteins to adsorb quinidine from highly dilute 
solution. N.  RAPHAEL  SHULMAN  679 
(c) Affinity of intact platelets  and treated platelets for quinidine: 
It was found that  platelets could be treated  in various ways to decrease their nitrogen 
content without affecting their activity in complement-fi~ing reactions (Table II). As shown in 
Table III, intact platelets (Prep. 1, Table II) adsorbed quinidine in amounts proportional to 
the  concentration  of quinidine in which  they were incubated,  washed  platelets  (Prep.  2) 
adsorbed much less quinidine, and platelet "ghosts" (Prep. 3) adsorbed no measurable amount 
of quinidine. Since the activity per platelet in complement-fixing reactions remained approxi- 
mately the same in the different preparations, it might appear that adsorption of quinidine 
by platelet was not the initial step in complex formation. However, because quinidine even 
at 10  -5"16 M concentration (3.6 #g. quinidine gluconate/ml.) was in large excess compared to 
TABLE III 
Adsorption of Quinidine by Platelets Treated as in Table II 
Sedimented platelets from suspensions prepared as in Table II were resuspended in differ- 
ent concentrations of quinidine, incubated  1 hour at 25  °, sedimented again, and quinidine 
content of the supernatant  fluid determined spectrophotometrically. Amounts of quinidine 
adsorbed  were equivalent to decreases in quinidine concentration in the supernatant  fluid. 
Quinidine gluconate, 0.01 mg./ml, equivalent to 10  ~.n g  quinidine. 
Cone. of quinidine  gluconate 
m~lml. 
O.Ol 
0.~ 
0.1 
0.3 
1.0 
3.0 
Micrograms quinidine gluconate adsorbed per milUliter  by: 
Prep. 2 
2 ×  10  o  platelets/ml. 
Prep. 1 
2 X 10  ~  platelets/ml. 
3.8 
6.6 
20.0 
33.2 
104.0 
152.0 
1.3 
2.8 
9.1 
40.0 
93.0 
Prep. 3 
approx. 4 X 10' 
platelets/mL 
0 
0 
0 
0 
0 
the amount of antibody taking part in complement-fixing reactions (see Fig. 7), it is possible 
that amounts of quinidine required for the reactions could be adsorbed by plateht "ghosts" 
and yet be insufficient for detection by the method of chemical analysis used. Any quinidine 
which was adsorbed by 109 intact platelets incubated in 10  ~'7~ ~t quinidine was not retained 
in suificient amount to cause complement fixation when the platelets were thereupon mixed 
with 3  ml.  of saline,  immediately sedimented,  and  resuspeuded  in the presence of excess 
antibody. Therefore any reaction between quinidine and platelets which might have occurred 
was rapidly reversible. 
(d) A.O~nity of the complete complex for quinidine: 
Reactions involving the removal of quinidine from the antibody-quinidine-platelet complex 
were slow compared with reactions involving quinidine in the initial step of complex formation. 
When a complex, which was formed in 0.5 ml. of 10  4"72 M quinidine with an optimal anti- 
body:platelet ratio, was sedimented by centrifugation and  resuspended in 0.5 ml. of saline 
containing complement, the amount of complement fixed was approximately 90 per cent of 
that fixed when the same complex was resuspended in 0.5 mi. of 10  "~'7~ M quinidine containing 
complement. Thus, the rate of complement fixation was more rapid than the rate of dissoeia- 680  TMMUNO1LEACTIONS INVOLVING  PLATELETS.  I 
tion of quinidine from the complete complex. Complete reversal of the complex by dissocia- 
tion of quinidine required comparatively long periods of time to take place, as shown in Fig. 
10. Dissociation of quinidine from the complex by dialysis also required longer periods of time 
than removal of quinidine from serum alone. When the complete complex, made by adding 
an optimal concentration of platelets to the same mixture of patient's serum plus quinidine 
used in Fig. 9, was dialyzed against saline and tested periodically for quinidine content as in 
Fig. 9, but without additional platelets, apparent  decreases in quinidine concentration took 
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Fro. 10. Dissodation of the complete complex during incubation in saline. A series  of tubes 
containing 2.8 units of antibody, optimai platelet concentration, and 10  -~x~ u quinidine in a 
0.5 ml. volume were incubated for 1 hour, centrifuged, and the supematant fluid removed. 
Each complex consisting of antibody attached to sedimented platelets was resuspended  in 3 
m]. of saline, and after periods of incubation at room temperature the complexes  were sedi- 
mented again and resuspended  in 0.5 ml. of 10  --9-'9 ~ q~dnidine  containing  complement for the 
usual measurement of complement fixation. Controls, designed to measure  degree  of dissocia- 
tion of the complex caused by an increase  in volume alone, consisted  of complexes  formed at 
10  -8-~" M quiaidine (in a 0.5 ml. volume) which were resuspended  for varied intervals in 3 m]. 
of 10  -a'~2 ~r quinidine, sedimented, and resuspended  again in 0.3 ml. of 10  -2"9 ~r qutnidine 
containing complement for complement fixation. 100 per cent complement fixation was equiva- 
lent to the amount of complement fixed by the complex formed in 0.S ml. of 10  -a'7~ M quin- 
idine, sedimented, and resuspended directly in 0.S ml. of 10  -~'9 M quinidine containing com- 
plement.  (O--O)  control, complexes incubated  in 3  ml. of quinidine;  (O--O)  complexes 
incubated in 3 ml. of saline. 
two to three times longer to occur than equivalent decreases in quinidine concentration in 
plain serum. It therefore appeared that quinidine was bound much more strongly in the anti- 
body-quinidine-platelet complex than by antibody or platelets alone. 
It is worthy of note that once complement was fixed by the complex, dissociation of the 
complex by incubation in saline or by dialysis did not result in recovery of complement activity 
in spite of the fact that antibody and platelets could be recovered from the dissociated com- 
plex with unaltered activity. Complement fixation in all of the above experiments appeared 
to be a stoichiometric reaction, and any equilibrium existing between the complex and comple- 
ment appeared to be far to the right (e.g. Table I). Failure to recover complement following 
reversal d  the complex therefore implied that complement fixed by the complex was altered, 
either when bound or when dissociated, in such a way that its activity could no longer be 
measured by usual techniques. N,  RAPHAEL  SHULMAN  681 
7.  Nature of tke Platelet Component Involved in Complex Formation.--Platelet 
"ghosts",  the  recognizable  remnants  of  individual  platelets  containing  as 
little as 20 per cent of the original platelet nitrogen (Prep. 4, Table II), were 
as active in complement-fixing reaction as a similar number of intact platelets. 
This suggested that the membranous portion of platelets contained the com- 
ponent  necessary  for  complex  formation.  When  a  platelet  suspension  was 
triturated  in  a  glass  tissue  homogenizer  to  produce  particulate  fragments 
showing  Brownian  motion,  complement-fixing  activity  was  present  in  the 
slightly opalescent filtrate of the suspension obtained with Whatman No. 1 filter 
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FzG. 11. Effect of heat on the complement-fixing activity of platelets. Aliquots of a saline 
suspension of platelets were heated for varying periods at different temperatures as indicated 
on the graph. Per cent activity of heated suspensions was based on the relative volume of 
suspension required to produce equivalent increments of complement  fixation in the presence 
of excess antibody and an optimal quinidine concentration in the usual complement-fixing 
mixture. 100 per cent activity was that obtained with the unheated aliquot. There was no 
loss in activity when platelets were heated for 1 hour at 45 °. Platelets heated at 60  ° for 15 
minutes showed morphological  changes no more marked than in Prep. 2, Table II. 
paper, but no activity remained in the clear filtrate obtained with a fritted-giass 
filter. Particulate platelet material was essential for complement fixation in all 
platelet  fractions  tested.  Complement-fixing  activity  of  platelets  persisted 
in strongly acid but not in strongly alkaline solution and was only moderately 
decreased by dehydrating platelets in air. The manner in which complement- 
fixing activity decreased when platelets were heated (Fig.  11) suggested that 
the platelet material involved in the reaction might be proteinaceous in nature. 
Platelets heated at 50  ° for 15 minutes had no complement-fixing activity and 
also did not adsorb antibody, indicating that the platelet component involved 
in complex formation had been destroyed. 
DISCUSSION 
A  mechanism for the molecular associations  involved in formation of the 
antibody-quinidine-platelet  complex  and  in  fixation of  complement  by  the 682  YM'MU'NOREACTIONS INVOLVING PLATELETS.  I 
complex could be deduced from the experimental results. There was evidence 
only of stoichiometric combination between the  four reactants  and  the  re- 
actions were most likely bimolecular and sequential. The sequence appeared 
to be, first, combination of quinldine with either antibody or platelets, next, 
formation of  the  complete  antibody-quinldine-platelet complex,  and finally, 
binding of complement by the  complex.  Whether  quinldine combined with 
antibody or  platelets in  the  initial  step  could  not  be  determined  on  the 
basis of data obtained. The rate-limiting step was formation of the complete 
complex. The rate constant of the reaction was dependent on quinidine con- 
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FZG. 12, Schematic representation of the model. Complex 3 is the type which binds com- 
plement; others are examples of types which do not bind complement.  The distribution  of the 
number of qulnidine molecules  in the complex  would be determined  by quinidine  concentra- 
tion, complexes 1 and 2 being more frequent at low quinidine  concentrations,  and complexes 
4 and 5 more frequent at high quinidine concentrations. The frequency with which anti- 
bodies would be attached  as nearest neighbor pairs would be determined by the antibody: 
platelet ratio. 
centration alone and quinidine was  always in  large  excess  compared to the 
amount of antibody. Some conclusions could be drawn concerning the spatial 
and  stoichiometric  relationship  between  the  reactants.  In  view  of their 
large size, platelets (or particulate platelet fractions) could be considered  to 
provide surfaces containing numerous sites for antibody attachment. The de- 
pendence of complement fixation on the number of antibodies attached per 
platelet  suggested  that  proximity of  attached  antibodies  was  essential  for 
complement to be bound. Compared to the findings at optimal quinidine con- 
centration,  complement  fixation  at  above-optimal  qulnidine  concentration 
was decreased with no change in the amount of antibody adsorbed per platelet, 
and  complement  fixation  at  suboptimal  quinldine  concentration  was  de- 
creased much more than the amount of antibody adsorbed per platelet. As- 
suming that the number of quinidine molecules effeeting attachment of anti- 
body to platelet varied with  quinidine concentrations, it  was possible  that C0MP.  FIX. 
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FIO. 13. Theoretical results; platelet concentration varied, antibody concentration con- 
stunt. Calculations were made using Equations 21, 23, and 24 of Paper II. Arbitrary values, 
found to be convenient  for computation, were assigned to terms proportional to the concen- 
tration of quinidine  (q in Equation 21),  of platelets (p in Equation 23),  and of antibody 
(A in Equation 23). The term 0', was calculated using Equation 21, and the term 0= was cal- 
culated using Equation 23. Values proportional to the amount of complement  fixed, C, were 
then calculated using Equation 24. A single quinidine concentration (q =  1.3, log q --- 0.114), 
which was found to be optimal (see Fig. 16), was used throughout. Relationships between 
antibody and platelet concentration and  the amount  of complement  bound were  propor- 
tionately similar when calculations were made using antibody values from 2.5 to 25. 
complement  was  fixed  only  when  antibodies  were  attached  by  an  optimal 
number  of  quinidine  molecules.  Complement  was  considered  to  have  the 
properties of a  molecule.  Because  the  apparent equilibrium between  comple- 
ment and the complex was far to the right, it could be assumed that a  "com- 
plement molecule" would  be bound  whenever  an  appropriate site for  its at- 
tachment was available. 
The  following  model  for  the  reaction  incorporates  the  above  conclusions 684  TMMUNOREACTIONS  INVOLVING  PLATELETS.  I 
in what appears to be the simplest form. Platelets provide surfaces containing 
a  distribution of independent equivalent sites for antibody attachment.  Each 
site can be occupied by one antibody and as many as three  quinidine mole- 
cules. An antibody will not occupy a site when there is no quinidine molecule 
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FIO. 14. Theoretical results; antibody concentration varied, platelet concentration con- 
stant. See Fig. 13. 
associated but can occupy a site along with one, two, or three quinidine mole- 
cules.  It is possible  that quinidine attaches first to an antibody which  then 
occupies a  platelet site or attaches first to a  platelet site which  is  then oc- 
cupied by an antibody. Complement can be bound between antibodies when- 
ever  each  of  two  neighboring  platelet  sites  is  occupied  with  one  antibody N.  RAP]~EL  S]t"ULMAN  685 
and two quinidine molecules. Complement will not be bound if the sites oc- 
cupied by antibodies are not nearest neighbors or do not each contain exactly 
two quinidine molecules. The model is represented schematically in Fig.  12. 
This model was amenable to mathematical description. Dr. Terrell L. Hill, 
considering that  the  steps  of  the  reaction  could be treated mathematically 
in  the  same  manner  as  association  between  molecules  in  dilute  solutions, 
derived  formulae  describing  the  properties  of  the  assumed  system 
using methods of statistical mechanics. He incorporated the principles of the 
model into equations in such a way that theoretical results could be calculated 
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FIG.  15.  Theoretical results; concentration of antibody and platelets varied maintaining 
an optimal antibody:platelet ratio. See Fig. 13. 
by  assigning values for concentration of reactants as they were used experi- 
mentally. Dr. Hill's derivations are in Paper II of this series. In one derivation 
it was assumed that quinidine was bound first by antibody and in the other 
that quinidine was bound first by platelets. Both derivations gave the same 
final equation for use in theoretical calculations. Arbitrary values, found to be 
convenient for computation, were assigned to terms in the equation represent- 
ing antibody, platelet, and quinidine concentrations to calculate the theoretical 
amount of complement fixed under various conditions. 
Theoretical results in Figs. 13, 14, and 15 correspond to experimental results 
in Figs. 1, 2, and 3, respectively. These figures show effects of varying antibody 
and platelet concentrations on the amount of complement fixed in the presence 
of a constant, optimal concentration of quinidine. Theoretical curves of comple- 
ment fixation with varied quinidine concentration are shown in Fig. 16 which 686  IMMUNOREACTIONS  INVOLVING  PLATELETS.  I 
correspond to experimental results in Fig. 4. The theoretical amount of antibody 
bound  by  platelets  and  the  platelet  concentration  required  for  maximum 
complement  fixation  when  quinidine  concentration  was varied  are  shown in 
Fig.  17 which  corresponds  to experimental  results in  Figs.  5  and  6.  Because 
there was no way of relating  assigned values to actual quantities  of reagents 
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Fzo.  16.  Theoretical results; quinldine concentration  varied, antibody:platelet  ratio 
constant. Calculations made as in Fig. 13 but quinidine concentration varied. 
used experimentally,  only qualitative  comparisons  of experimental  and  theo- 
retical results were possible. In each case experimental  and theoretical results 
were quite similar. 
The  most  evident  difference between experimental  and  theoretical  results 
involved  the  amount  of complement  fixed and  the  amount  of antibody ad- 
sorbed  with  changes  in  quinidine  concentration.  The  theoretical  amount  of 
antibody adsorbed (Fig.  17) changed more abruptly with changes in quinidine 
concentration  than  did  the measured amount  of antibody adsorbed  (Fig.  6), N.  RAPHAEL  SHULMAN  687 
and the quinidine concentrations required for theoretical curves of complement 
fixation  covered half as many decades  on a  log  scale  as  the  quinidine  con- 
centrations  required  for  experimental  curves  of  complement  fixation  (of. 
Figs.  16 and 4).  In addition  the experimental curves of Fig. 4  had a  skewed 
configuration, but complications involved in using high quinidine concentrations 
experimentally (anti-complementary effect) may account for this. 
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FIo. 17. Theoretical results; effects of quiuidine concentration on platelet concentration 
required for maximum complement fixation and on amount of antibody bound by platelets. 
Solid llne curves of complement fixation calculated as in Fig. 13 with different values for 
quinidine concentration (see Fig. 16). Dashed line curves of amount of antibody bound cal- 
culated using Equation 25 of Paper II. Antibody concentration constant at A  =  10. Maxi- 
mum amount of complement fixed =  1.07. 
The model on which  the equations  were based represented  an attempt to 
describe  the  reactions  as  simply as  possible.  Thus  it  was  assumed  that  all 
quinidine and antibody molecules attached with equal ease and that all platelet 
sites or molecules of antibody were equivalent and had the same valence for 
quinidine.  The  actual  reactions  were no  doubt  complicated by a  number of 
factors such as: a specific distribution of heterogeneity of valence for qulnldine 
including the possibility that more than three quinidine molecules are involved 
per antibody (e.g.  12),  changes in  association constants  with  succeeding  at- 688  IM~IUNOREACTIONS  INVOLVING  PLATELETS.  I 
tachments  of  quinidine  or  antibody  molecules,  the  possibility of  sterically 
determined  order  of  addition  of  quinidine  molecules,  and  possible favored 
adsorption  of antibody with  a  specific number of quinidine  linkages.  All  of 
these  possible complications  would not  fundamentally  change  the  concepts 
of the model but could account for the observed differences between theoretical 
and  experimental results.  The fact that  experimental  and  theoretical results 
differed so little  suggests  that  the  model resembles  approximately  the  true 
mechanism  and  sequence  of  reactions  involved  in  complex  formation  and 
fixation  of complement by the complex. 
It has generally been considered that antibodies which attach  to platelets 
or other cells have been formed either against some specific cellular  substance 
or against some common antigen shared by the cells. If it had been demon- 
strated that quinidine  combined with platelets in the initial step of antibody- 
quinidine-platelet  complex  formation  it  could  have  been  concluded  that  a 
platelet substance in combination with quinidine was the antigenic component 
of the reaction. But it was not possible to determine experimentally whether 
antibody or platelets combined first with quinidine,  and mathematical deriva- 
tions based on both possibilities  resulted in the same final equations for theo- 
retical calculations.  It therefore appeared equally possible that platelets were 
not part of the antigen. 
The  assumption  that  platelets  in  combination  with  quinidine  form  the 
antigen necessitates making other assumptions which are not in accord with 
previous  immunologic  observations.  For  instance,  it  would be necessary to 
assume that individuals who develop sensitivity have a peculiar ability to form 
antibodies against very weakly adsorbed haptene, as was suggested by Ackroyd 
(5).  In  addition,  if platelet-protein  in  combination  with  quinidine  were the 
antigen, inhibition of antibody attachment by haptene might be expected (13), 
but was not observed even at  the highest  possible quinidine  concentrations 
used experimentally. There may have been sufficient  competition by the pro- 
tein portion of the antigen with antibody for haptene to prevent such inhibi- 
tion; but this would be a  unique immunologic  reaction in contrast with the 
usual  circumstances  in  which  a  pre-formed  protein-haptene  antigen  may 
compete more strongly than haptene alone for antibody (13). 
An alternate  possibility is  that  the antibody may be formed,  not against 
platelets with weakly adsorbed haptene, but against some non-specific protein 
combined with haptene.  In this case the antigen  could be a  stable complex, 
possibly with an oxidative product of the haptene (13), which would be more 
likely  to  promote  antibody formation.  Combination  between antibody  and 
haptene could be considered  to take place in the classical manner  (13).  Anti- 
body, which was unable to be adsorbed by platelets in the absence of haptene, 
would acquire that ability when combined with haptene. Platelets would enter 
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with appropriate charges  and configuration to permit attachment of antibodies 
containing haptene molecules.  Such adsorption of antibody would be similar 
to the non-specific  adsorption of various proteins on membranes of platelets 
and  other  cells  (14,  15).  Haptene inhibition  of antibody attachment  would 
not be expected to occur. The idiosyncrasy would not necessarily involve an 
unusual  ability to  form antibodies  against  a  weakly adsorbed haptene,  but 
might involve some other peculiarity such as the formation of a stable antigenic 
protein complex with an abnormal metabolite of a certain drug. Similar diseases 
of sensitivity associated with attachment of antibodies to cells would not have 
to be considered the result of antibody formation against  a  specific cellular 
antigen.  It  is possible that  certain  antibodies  may interact  non-specifically 
with cellular  membranes conducive to their adsorption; and in some instances 
the adsorbed antibody may be injurious to the cell. 
Conclusions drawn in the present study concerning  the nature of complement 
and complement-fixing  reactions should be as valid as those concerning  anti- 
body-quinidine-platelet complex formation. These concepts may have applica- 
tion  in  further  elucidating  the  controversial  nature  of complement  activity 
(16-18). 
SI.rMM&Ry 
A  steric  and  kinetic  model for the  sequence and  mechanism  of reactions 
leading to formation of a  complex from an antibody, a haptene  (quinidine), 
and a cell membrane (platelets), and to fixation of complement by the complex 
was  deduced from  the  effects of varying  the  initial  concentration  of  each 
component of the complex on the amount of complement fixed, from kinetic 
aspects  of  the  sequential  reactions,  and  from  other  chemical  and  physical 
properties of the various components involved. Theoretical results calculated 
using equations based on the model, which were derived by Dr. TerreU L. Hill, 
were similar  in all respects to experimental results. Results of this study were 
consistent with the possibilities  that the protein moiety of a haptenic antigen 
involved in development of an antibody which attaches to a cell is not neces- 
sarily a component of the cell, and that the cell reacts with the antibody by 
virtue  of  having  a  surface  favorable  for  non-specific  adsorption  of  certain 
haptene-antibody complexes. 
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